将血脂蛋白结合纳入生理学基础的药理动力学模型的含义:用阿米奥达龙进行模拟研究
Kosuke Doki1,2, Naoaki Hashimoto2, Keigo Yoshida2
1Department of Pharmaceutical Sciences, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Clinical pharmacology and therapeutics
|December 14, 2023
概括
基于生理学的药理动力学 (PBPK) 模型可以通过包括脂蛋白结合来更好地预测阿米奥达龙清除. 这种方法提高了与脂蛋白相关的药物的个体间变异性预测的准确性.
科学领域:
- 药理动力学 药理动力学
- 药物新陈代谢 药物新陈代谢
- 计算生物学 计算生物学
背景情况:
- 脂蛋白结合显著影响血中的脂性药物度.
- 目前的生理学基础的药理动力学 (PBPK) 模型经常忽视脂蛋白结合.
- 阿米奥达龙广泛与富含甘油的血清脂蛋白结合,影响血总度.
研究的目的:
- 为了研究脂蛋白结合对阿米奥达龙药理动学的影响.
- 开发和验证一个包含血脂蛋白结合的PBPK模型 (LPP模型).
- 评估脂蛋白结合对阿米奥达龙未结合部分和全身清除的影响.
主要方法:
- 开发了一种阿米奥达龙PBPK模型 (LPP模型),用于计算血清甘油三水平和脂蛋白结合.
- 将LPP模型与仅考虑白蛋白结合的基础PBPK模型进行比较.
- 利用PBPK建模和模拟来预测药物度和清除.
主要成果:
- 在LPP模型显示更大的变化系数,与观察到的数据比基准模型更好地调整.
- 在LPP模型中,总血amiodarone度随着较高的脂蛋白结合和白蛋白水平的增加而增加.
- 稳定状态下未结合的血amiodarone度不受脂蛋白结合或白蛋白水平变化的影响.
结论:
- 将血脂蛋白结合纳入PBPK模型可以提高预测准确度,从而提高阿米奥达龙清除的个体间变异性.
- LPP模型更可靠地预测了阿米奥达龙未结合部分的个体间变异性.
- 对脂蛋白相关药物的PBPK建模应考虑血脂蛋白结合,特别是在超脂血症的情况下.
相关概念视频
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
41
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
41
01:13Physiological Pharmacokinetic Models: Assumption with Protein Binding
46
Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
46
00:57Physiological Pharmacokinetic Models: Blood Flow-Limited Versus Diffusion-Limited Models
84
Physiological pharmacokinetic models, often called flow-limited or perfusion models, typically assume a swift drug distribution between tissue and venous blood, creating a rapid drug equilibrium. This premise is based on the idea that drug diffusion is extremely fast, and the cell membrane presents no barrier to drug permeation. In this scenario, where no drug binding occurs, the drug concentration in the tissue equals that of the venous blood leaving the tissue. This greatly simplifies the...
84
01:29Drug Distribution: Plasma Protein Binding
5.6K
Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
5.6K
01:15Model Approaches for Pharmacokinetic Data: Physiological Models
47
Physiological models in pharmacokinetics are instrumental in understanding the distribution and elimination of drugs within the body. These models describe the drug concentration within target organs, influenced by factors such as drug uptake, tissue volume, and blood flow. Drug uptake is governed by the partition coefficient, which signifies the drug concentration ratio in tissue to that in the blood. The blood flow rate to a specific tissue is expressed as Qt, and the rate of change in tissue...
47
01:09Hepatic Drug Clearance: Effect of Protein Binding
205
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
205